Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy

It remains unclear why the clinically used anti-CTLA-4 antibodies, popularly called checkpoint inhibitors, have severe immunotherapy-related adverse effects (irAEs) and yet suboptimal cancer immunotherapeutic effects (CITE). Here we report that while irAE-prone Ipilimumab and TremeIgG1 rapidly direc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Res
Main Authors: Zhang, Yan, Du, Xuexiang, Liu, Mingyue, Tang, Fei, Zhang, Peng, Ai, Chunxia, Fields, James K., Sundberg, Eric J., Latinovic, Olga S., Devenport, Martin, Zheng, Pan, Liu, Yang
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796842/
https://ncbi.nlm.nih.gov/pubmed/31267017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41422-019-0184-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados